Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Chem Commun (Camb) ; 54(39): 4947-4950, 2018 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-29700524

RESUMO

We herein present pioneering studies to reveal that excitation-wavelength-dependent photoluminescence properties of fluorescent silicon nanoparticles (SiNPs) can be realized by rationally designing surface ligands, i.e., several kinds of oxidized indole derivatives. The resultant ligand-decorated SiNPs exhibit strong fluorescence, with significant excitation-wavelength-dependent emissive shifting from ∼420 nm to ∼550 nm. Taking advantage of their unique optical merits, we further exploit the resultant ligand-decorated SiNPs as novel fluorescent labels for anti-counterfeiting and cell imaging.

2.
J Microbiol Immunol Infect ; 48(6): 597-603, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24863497

RESUMO

PURPOSE: To preliminarily evaluate the immunogenicity and efficacy of the recombinant tuberculosis vaccine AEC/BC02 in which Ag85b and fusion protein ESAT6-CFP10 were combined with bacillus Calmette-Guérin CpG and an aluminum salt-based adjuvant system. METHODS: Groups of BALB/c mice were immunized intramuscularly three times at 10-day intervals with AEC/BC02 or the adjuvant alone and the vaccine-induced cell-mediated immune responses were evaluated. The efficacy of AEC/BC02 was evaluated in two guinea pig models, one a model of prevention and the other a model of latent infection. RESULTS: The AEC/BC02 vaccine induced strong cellular immune responses characterized by a high frequency of antigen-specific interferon-γ-secreting T cells in mice at different time points after the last vaccination. In the preventive model of guinea pig, AEC/BC02 did not protect against Mycobacterium tuberculosis as a pre-exposure vaccine. However, in a latent infection model of guinea pig, it effectively controlled the reactivation of M. tuberculosis and lowered the bacterial load in the lung and spleen. CONCLUSION: These results indicate AEC/BC02 can protect against reactivation of latent infection and may function as a therapeutic vaccine.


Assuntos
Antígenos de Bactérias/imunologia , Tuberculose Latente/imunologia , Mycobacterium tuberculosis/imunologia , Células Th1/imunologia , Vacinas contra a Tuberculose/imunologia , Vacinas Sintéticas/imunologia , Animais , Anticorpos Antibacterianos/imunologia , Vacina BCG/imunologia , Carga Bacteriana/imunologia , Modelos Animais de Doenças , Cobaias , Interferon gama/imunologia , Interferon gama/metabolismo , Tuberculose Latente/microbiologia , Tuberculose Latente/prevenção & controle , Pulmão/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Baço/microbiologia , Vacinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...